217 related articles for article (PubMed ID: 28434798)
1. Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial.
Welz S; Mönnich D; Pfannenberg C; Nikolaou K; Reimold M; La Fougère C; Reischl G; Mauz PS; Paulsen F; Alber M; Belka C; Zips D; Thorwarth D
Radiother Oncol; 2017 Sep; 124(3):526-532. PubMed ID: 28434798
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation to hypoxic subvolumes in head and neck cancer: A randomized phase II study using dynamic [
Welz S; Paulsen F; Pfannenberg C; Reimold M; Reischl G; Nikolaou K; La Fougère C; Alber M; Belka C; Zips D; Thorwarth D
Radiother Oncol; 2022 Jun; 171():30-36. PubMed ID: 35395276
[TBL] [Abstract][Full Text] [Related]
3. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
4. Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer.
Boeke S; Thorwarth D; Mönnich D; Pfannenberg C; Reischl G; La Fougère C; Nikolaou K; Mauz PS; Paulsen F; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1571-1576. PubMed ID: 28891398
[TBL] [Abstract][Full Text] [Related]
5. Effect of [(18)F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice.
Schütze C; Bergmann R; Brüchner K; Mosch B; Yaromina A; Zips D; Hessel F; Krause M; Thames H; Kotzerke J; Steinbach J; Baumann M; Beuthien-Baumann B
Radiother Oncol; 2014 Apr; 111(1):81-7. PubMed ID: 24636842
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-guided adaptive radiation dose escalation in head and neck carcinoma: a planning study.
Servagi-Vernat S; Differding S; Sterpin E; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
Acta Oncol; 2015 Jul; 54(7):1008-16. PubMed ID: 25562382
[TBL] [Abstract][Full Text] [Related]
7. Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol.
Pigorsch SU; Wilkens JJ; Kampfer S; Kehl V; Hapfelmeier A; Schläger C; Bier H; Schwaiger M; Combs SE
Radiat Oncol; 2017 Mar; 12(1):45. PubMed ID: 28249612
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of
Berwouts D; Madani I; Duprez F; Olteanu AL; Vercauteren T; Boterberg T; Deron P; Bonte K; Huvenne W; De Neve W; Goethals I
Head Neck; 2017 Nov; 39(11):2264-2275. PubMed ID: 28833829
[TBL] [Abstract][Full Text] [Related]
9. FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
Bandurska-Luque A; Löck S; Haase R; Richter C; Zöphel K; Abolmaali N; Seidlitz A; Appold S; Krause M; Steinbach J; Kotzerke J; Zips D; Baumann M; Troost EGC
Radiother Oncol; 2019 Jan; 130():97-103. PubMed ID: 30293643
[TBL] [Abstract][Full Text] [Related]
10. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
11. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy.
Chao KS; Bosch WR; Mutic S; Lewis JS; Dehdashti F; Mintun MA; Dempsey JF; Perez CA; Purdy JA; Welch MJ
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1171-82. PubMed ID: 11240261
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: a biological modeling study.
Chang JH; Wada M; Anderson NJ; Lim Joon D; Lee ST; Gong SJ; Gunawardana DH; Sachinidis J; O'Keefe G; Gan HK; Khoo V; Scott AM
Acta Oncol; 2013 Nov; 52(8):1723-9. PubMed ID: 23317145
[TBL] [Abstract][Full Text] [Related]
13. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
[TBL] [Abstract][Full Text] [Related]
14. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial.
Mortensen LS; Johansen J; Kallehauge J; Primdahl H; Busk M; Lassen P; Alsner J; Sørensen BS; Toustrup K; Jakobsen S; Petersen J; Petersen H; Theil J; Nordsmark M; Overgaard J
Radiother Oncol; 2012 Oct; 105(1):14-20. PubMed ID: 23083497
[TBL] [Abstract][Full Text] [Related]
15. Potential of [18F]-fluoromisonidazole positron-emission tomography for radiotherapy planning in head and neck squamous cell carcinomas.
Henriques de Figueiredo B; Merlin T; de Clermont-Gallerande H; Hatt M; Vimont D; Fernandez P; Lamare F
Strahlenther Onkol; 2013 Dec; 189(12):1015-9. PubMed ID: 24173497
[TBL] [Abstract][Full Text] [Related]
16. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
17. A multicentric randomized controlled phase III trial of adaptive and 18F-FDG-PET-guided dose-redistribution in locally advanced head and neck squamous cell carcinoma (ARTFORCE).
de Leeuw ALMP; Giralt J; Tao Y; Benavente S; France Nguyen TV; Hoebers FJP; Hoeben A; Terhaard CHJ; Wai Lee L; Friesland S; Steenbakkers RJHM; Tans L; Heukelom J; Kayembe MT; van Kranen SR; Bartelink H; Rasch CRN; Sonke JJ; Hamming-Vrieze O
Radiother Oncol; 2024 Jul; 196():110281. PubMed ID: 38636708
[TBL] [Abstract][Full Text] [Related]
18. Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma.
Zegers CM; van Elmpt W; Hoebers FJ; Troost EG; Öllers MC; Mottaghy FM; Lambin P
Acta Oncol; 2015; 54(9):1378-84. PubMed ID: 26213313
[TBL] [Abstract][Full Text] [Related]
19. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.
Servagi-Vernat S; Differding S; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1544-52. PubMed ID: 24570097
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
